Founded in 2004, ERYTECH Pharma develops innovative cancer therapies that work by starving tumours. Its first product, which is in phase III development, provides a therapeutic solution to frail patients with acute leukaemia.

ERYTECH proprietary technology is based on encapsulation of therapeutic molecules into red blood cells.

The company has a production unit located in Lyons with “Pharmaceutical Establishment” status. It has signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.


> Show all


ERYTECH Pharma reports revenues and cash balance for the fourth quarter of 2014 and provides an update on upcoming milestones


ERYTECH today announced the launch of a sponsored American Depository Receipt (ADR) Level 1 listing in the United States in order to support the expansion of the Company’s US investor base.


ERYTECH today announced that Pierre-Olivier Goineau will be leaving the company to pursue other interests.


ERYTECH reports additional positive Phase III results from the pivotal study with ERY-ASP/GRASPA® in Acute Lymphoblastic Leukemia


> Show all

March 9-11, 2015

PARTNERING – ERYTECH Pharma participates in BIO Europe Spring 2015 which takes place in Paris, France from March 9 to 11, 2015

February 23, 2015

FINANCE – ERYTECH Pharma attends 3rd ANNUAL Sachs Cancer Bio Partnering & Investment Forum on February 23rd, 2015, New York City, NY, USA

February 22-25, 2015

SCIENTIFIC CONGRESS – ERYTECH Pharma attends Acute Leukemia XV from February 22 to 25, 2015 in Munich, Germany

February 9-10, 2015

FINANCE – ERYTECH Pharma participates on February 9-10, 2015 to BIO CEO INVESTOR Conference taking place in New York City, NY, USA